High Health-Care Utilization (HCU) and Costs Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients

被引：0
|
作者：
Gordon, Stuart
Fraysse, Jeremy
Li, Suying
Ozbay, A. Burak
Wong, Robert
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1253-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1253-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] High prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in type 2 diabetes mellitus
    Thiruppathi, Shankar
    Falck-Ytter, Yngve
    Dasarathy, Srinivasan
    Rogers, Nicholette
    McCullough, Arthur J.
    HEPATOLOGY, 2006, 44 (04) : 660A - 660A
  • [22] Clinical and liver histological differences in patients with nonalcoholic fatty liver disease (NAFLD) with and without diabetes mellitus (DM)
    Lee, Ye-Jin
    Jensen, Donald M.
    Te, Helen S.
    Reau, Nancy
    Reddy, Kapuluru G.
    Satoskar, Rohit S.
    Mishra, Poonam
    Hart, John
    Mohanty, Smruti R.
    GASTROENTEROLOGY, 2008, 134 (04) : A782 - A782
  • [23] DIAGNOSING NONALCOHOLIC STEATOHEPATITIS (NASH) AMONG PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): FEQUENCY AND PREDICTORS OF NAFLD ACTIVITY SCORE MEASUREMENT
    Katz, J.
    Heinz, S.
    DiBonaventura, M.
    VALUE IN HEALTH, 2017, 20 (05) : A180 - A180
  • [24] Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databases
    Marchesini, G.
    Ting, J.
    Saragoni, S.
    Esposti, L. Degli
    Ozbay, A. B.
    Petta, S.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E27 - E27
  • [25] Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
    Terai, Shuji
    Buchanan-Hughes, Amy
    Ng, Alvin
    Lee, I-Heng
    Hasegawa, Ken
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (03) : 274 - 284
  • [26] Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
    Shuji Terai
    Amy Buchanan-Hughes
    Alvin Ng
    I-Heng Lee
    Ken Hasegawa
    Journal of Gastroenterology, 2021, 56 : 274 - 284
  • [27] Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Jain, Mukul R.
    Giri, Suresh R.
    Bhoi, Bibhuti
    Trivedi, Chitrang
    Ranvir, Ramchandra
    Kadam, Shekhar
    Swain, Prabodha
    Patel, Pankaj R.
    DIABETES, 2015, 64 : A503 - A503
  • [28] Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system
    Kato, Hiroyuki
    Isaji, Shuji
    Azumi, Yoshinori
    Kishiwada, Masashi
    Hamada, Takashi
    Mizuno, Shugo
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (03) : 296 - 304
  • [29] Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0
    Vairetti, Mariapia
    Colucci, Giuseppe
    Ferrigno, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [30] Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
    Vairetti, Mariapia
    Colucci, Giuseppe
    Ferrigno, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
12345